Proactive Investors - Run By Investors For Investors

Catabasis surges after successful mid-stage trial of its DMD treatment

Catabasis’ edasalonexent tablet helped to preserve muscle function and sustained “disease-modifying effects” in boys with DMD, while no side effects were observed
boy walking on beach
DMD almost exclusively affects young boys and there is current no known cure

Catabasis Pharmaceuticals Inc (NASDAQ:CATB) surged on Tuesday after the biopharma reported positive results from a mid-stage study of its Duchenne muscular dystrophy treatment.

In the trial, the company’s edasalonexent tablet helped to preserve muscle function and sustained “disease-modifying effects” in boys with DMD, while no side effects were observed.

Consistent improvements in all assessments of muscle function were observed after more than a year of treatment compared to the rate of change in the pre-specified control period.

DMD is a rare muscle-wasting disease that almost exclusively affects only young boys, for which there is currently no known cure.

Importantly, Catabasis is looking to treat all DMD sufferers with edasalonexent rather than just a subset of patients.

A pivotal phase III trial is scheduled to get underway in the first half of this year, with top-line data expected in 2020.

“We are thrilled to see this preservation of muscle function and substantial slowing of disease progression in boys following more than a year of edasalonexent treatment. This effect has the potential to be extremely impactful for boys affected by Duchenne,” said chief executive Jill Milne.

“Building on the results previously reported for edasalonexent treatment in patients up to 36 weeks, these new data at 48 and 60 weeks show that edasalonexent continued to slow progression of the disease.”

Catabasis shares soared by a quarter to US$1.57 on Tuesday.

View full CATB profile View Profile

Related Articles

pills
July 25 2018
Under former chief executive Peter George and his successor Shaun Chilton, Clinigen has been transformed via a series of well-judged, quickly integrated and cash generative acquisitions
1538160791_petri-dishes.jpg
September 28 2018
The biotech group revealed it had brought in $9.1mln via an oversubscribed placing
man and woman working in a lab
October 11 2018
There were no adverse safety findings and excellent drug-like properties were confirmed.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use